We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Inhaler Regimen Fine for Hospitalized COPD Patients

By HospiMedica staff writers
Posted on 26 Mar 2002
A study has found that patients with severe chronic obstructive pulmonary disease (COPD) who are hospitalized for exacerbations and treated with a metered-dose inhaler (MDI) do just as well as those patients treated with an intravenous/nebulizer regimen. More...
The study was reported in the February 2002 issue of the Respiratory Care Journal.

The study was undertaken by researchers at two community hospitals in Bangor, Maine (USA), in order to determine if a simpler, less-expensive regimen of oral medications could produce the same therapeutic results as a more-expensive, resource-intensive regimen of intravenous drugs. The randomized study involved 34 patients with severe COPD and similar baseline demographic, laboratory, comorbidity, and ventilatory values. Of these, 19 patients received oral treatment via an MDI, while the other 15 patients were treated with an intravenous/nebulizer regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide.

Outcome variables that compared the MDI treatment to the intravenous treatment--including the mean change in forced expiratory volume in the first second (0.12 l vs 0.13 l), mean length of stay (4.3 vs 5.1 days), and treatment failures (32% vs 33%)-- showed no significant differences.



Related Links:
Respiratory Care Journal

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.